Every Form 4 that Biote Corp. (BTMD) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow BTMD and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BTMD filings page.
biote Corp. director and Executive Chairman Marc D. Beer reported two open-market purchases of Class A Common Stock. On August 10, 2026, he purchased 115,950 shares at a weighted average price of $1.53 per share in transactions ranging from $1.46–$1.55. On August 11, 2026, he purchased an additional 16,000 shares at a weighted average price of $1.55 per share, with trade prices between $1.53–$1.60. All reported holdings are direct, and these transactions total 131,950 shares of net buying.
biote Corp. interim CEO Robert Charles Peterson received a grant of stock options as part of his compensation. The award covers 206,746 options to purchase Class A common stock at an exercise price of $2.46 per share and expires on June 11, 2036. According to the vesting terms, 25% of the options will vest on June 12, 2027, with the remaining options vesting in 36 substantially equal monthly installments, subject to his continued service. Following this grant, Peterson holds 206,746 stock options directly, and the filing does not report any open-market share purchases or sales.
biote Corp. director Bret Christensen received a grant of stock options, giving him the right to buy 130,000 shares of Class A Common Stock. The options have an exercise price of $2.34 per share and expire on June 7, 2036.
All 130,000 option shares will vest on the earlier of June 8, 2027 or the day before biote Corp.'s 2027 Annual Meeting of Stockholders, as long as Christensen remains in continuous service through that vesting date.
biote Corp. Executive Chairman Marc D. Beer received a grant of employee stock options covering 114,157 shares of Class A Common Stock. The options have an exercise price of $2.34 per share and expire on June 7, 2036.
According to the vesting schedule, 25% of the options vest on June 8, 2027, with the remaining options vesting in 36 substantially equal monthly installments thereafter, subject to his continuous service. Following this grant, he holds 114,157 derivative securities related to these options.
biote Corp. director Andrew R. Heyer reported equity-based compensation awards. He received a stock option covering 130,000 shares of Class A Common Stock at an exercise price of $2.2000 per share, expiring on May 11, 2036. All shares under this option vest on the earlier of May 12, 2027 or the day before the company’s 2027 annual stockholder meeting, subject to his continuous service. He also received 35,259 Deferred Settlement RSUs, each economically equivalent to one share of Class A Common Stock. These RSUs are fully vested at grant but will settle only when he separates from service, and his Deferred Settlement RSU balance increased to 81,382 units after this award.
biote Corp. director Debra L. Morris reported compensation-related equity activity. She exercised derivative rights tied to Deferred Settlement RSUs into 21,407 shares of Class A Common Stock and now directly holds 71,562 common shares. She also received awards of 130,000 stock options with a $2.20 exercise price, expiring in 2036, and 39,036 Deferred Settlement RSUs that are fully vested but settle at future dates as described in the award terms.
biote Corp. director Stephen Mark Cone received new equity awards in the form of options and deferred settlement RSUs. He was granted stock options for 130,000 shares of Class A Common Stock at an exercise price of $2.20 per share, vesting in full on the earlier of May 12, 2027 or the day prior to the 2027 annual meeting, subject to continued service.
He also received 31,481 Deferred Settlement RSUs, each economically equivalent to one share of Class A Common Stock. These RSUs are fully vested upon grant, but settlement is deferred until his separation from service. Following these awards, he holds 130,000 options and 69,822 Deferred Settlement RSUs directly.
biote Corp. director Dana Lynn Jacoby received new equity awards. She was granted stock options for 130,000 shares of Class A Common Stock at an exercise price of $2.20 per share, expiring on May 11, 2036. These options vest on the earlier of May 12, 2027 or the day prior to the company’s 2027 annual stockholders meeting, subject to continued service.
She also received 37,777 Deferred Settlement RSUs, each economically equivalent to one share of Class A Common Stock. These RSUs are fully vested upon grant, with settlement deferred until calendar year 2027 or her separation from service, whichever occurs first. Following these awards, she holds 130,000 options and 59,364 Deferred Settlement RSUs directly.
biote Corp. director Marc D. Beer received a grant of stock options covering 195,000 shares of Class A common stock. The options have an exercise price of $2.20 per share and were awarded at no cost to him.
All 195,000 option shares will vest on the earlier of May 12, 2027 or the day before biote Corp.’s 2027 annual meeting of stockholders, as long as he continues in service through that date. Following this grant, he holds 195,000 stock options directly.
biote Corp. director and ten percent owner Richard R. Barrera received a grant of stock options for 121,452 shares of Class A Common Stock at an exercise price of $2.20 per share. The options vest on the earlier of May 12, 2027 or the day before the 2027 Annual Meeting of Stockholders and expire on May 11, 2036.
biote Corp. reported that General Counsel Daniel Michael Monico received a grant of 88,800 employee stock options for Class A common stock at an exercise price of $2.19 per share. Following the grant, he holds 88,800 options directly.
One-half of the options vest on April 27, 2028, with the remaining half vesting in 24 equal monthly installments after that date, contingent on his continued service. The options expire on April 30, 2036. This is a compensation-related award, not an open‑market purchase or sale.
biote Corp. reported that Chief Executive Officer Bret Christensen received a grant of employee stock options. The award covers 441,653 options to buy Class A Common Stock at an exercise price of $1.43 per share, all held as direct ownership.
According to the vesting terms, 25% of the options will vest on April 1, 2027. The remaining options will then vest in 36 substantially equal monthly installments, contingent on Christensen’s continuous service through each vesting date. No open‑market purchases or sales were reported in this filing.
biote Corp. Chief Financial Officer Robert Charles Peterson received a grant of 107,169 employee stock options for Class A Common Stock. The options have an exercise price of $1.43 per share and expire on March 31, 2036.
After this award, Peterson holds 107,169 derivative securities. According to the vesting schedule, 25% of the options vest on April 1, 2027, with the remaining options vesting in 36 substantially equal monthly installments thereafter, contingent on his continued service.